How should we better measure the cost-effectiveness of deprescribing interventions? Recommendations for improving value assessment
Hung A, Wang J, Moriarty F, et al. Value assessment of deprescribing interventions: Suggestions for improvement [published online ahead of print, 2023 Feb 21]. J
Key learnings from the OPTIMIZE deprescribing pragmatic trial
Sheehan OC, Gleason KS, Bayliss EA, et al. Intervention design in cognitively impaired populations-Lessons learned from the OPTIMIZE deprescribing pragmatic trial [published online ahead of
Multiple Comorbidities and Multiple Medications: The Challenges Facing Older Adults with Heart Failure
Kwak MJ, Cheng M, Goyal P, et al. Medication Complexity Among Older Adults with HF: How Can We Assess Better?. Drugs Aging. 2022;39(11):851-861. doi:10.1007/s40266-022-00979-2 Heart
How “age-friendly” are deprescribing interventions?
Wang J, Shen JY, Conwell Y, et al. How “age-friendly” are deprescribing interventions? A scoping review of deprescribing trials [published online ahead of print, 2022
Deintensifying diabetes medications: Beliefs and misconceptions among older adults
Pilla SJ, Meza KA, Schoenborn NL, Boyd CM, Maruthur NM, Chander G. A Qualitative Study of Perspectives of Older Adults on Deintensifying Diabetes Medications [published
Gabapentin as a substitute for opioids: Is the solution creating new problems?
Bongiovanni T, Gan S, Finlayson E, et al. Prolonged use of newly prescribed gabapentin after surgery [published online ahead of print, 2022 Aug 24]. J
